Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 135

Similar articles for PubMed (Select 16268665)

1.

Head-to-head comparison of the costs of atypical antipsychotics: a systematic review.

Barbui C, Lintas C, Percudani M.

CNS Drugs. 2005;19(11):935-50. Review.

PMID:
16268665
2.

Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review.

Hargreaves WA, Gibson PJ.

CNS Drugs. 2005;19(5):393-410. Review. Erratum in: CNS Drugs. 2005;19(9):784. Gibson, Joseph P [corrected to Gibson, P Joseph].

PMID:
15907151
3.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

4.

Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.

Yang YK, Tarn YH, Wang TY, Liu CY, Laio YC, Chou YH, Lee SM, Chen CC.

Psychiatry Clin Neurosci. 2005 Aug;59(4):385-94. Erratum in: Psychiatry Clin Neurosci. 2005 Oct;59(5):625-6. Tarn, Yeng Hui [corrected to Tarn, Yen-Huei].

PMID:
16048443
5.

Clinical trial-based cost-effectiveness analyses of antipsychotic use.

Polsky D, Doshi JA, Bauer MS, Glick HA.

Am J Psychiatry. 2006 Dec;163(12):2047-56. Review.

PMID:
17151153
6.

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

Laux G, Heeg B, van Hout BA, Mehnert A.

Pharmacoeconomics. 2005;23 Suppl 1:49-61.

PMID:
16416761
7.

The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.

Naber D, Lambert M.

CNS Drugs. 2009 Aug;23(8):649-59. doi: 10.2165/00023210-200923080-00002.

PMID:
19594194
8.

The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.

Achilla E, McCrone P.

Appl Health Econ Health Policy. 2013 Apr;11(2):95-106. doi: 10.1007/s40258-013-0016-2. Review.

PMID:
23494934
9.

Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.

Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA.

J Ment Health Policy Econ. 2008 Jun;11(2):89-97.

PMID:
18509216
10.

Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.

Knapp M, Windmeijer F, Brown J, Kontodimas S, Tzivelekis S, Haro JM, Ratcliffe M, Hong J, Novick D; SOHO Study Group.

Pharmacoeconomics. 2008;26(4):341-58.

PMID:
18370568
11.

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.

De Graeve D, Smet A, Mehnert A, Caleo S, Miadi-Fargier H, Mosqueda GJ, Lecompte D, Peuskens J.

Pharmacoeconomics. 2005;23 Suppl 1:35-47.

PMID:
16416760
12.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, BurĂ³n JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
13.

Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.

Yu W, Ren XS, Lee AF, Herz L, Huang YH, Kazis LE.

Pharmacoeconomics. 2006;24(12):1233-48.

PMID:
17129077
14.

The new atypical antipsychotics: a review of pharmacoeconomic studies.

Revicki DA.

Expert Opin Pharmacother. 2000 Jan;1(2):249-60. Review.

PMID:
11249546
15.
16.

Economics of atypical antipsychotics in bipolar disorder: a review of the literature.

Fleurence RL, Dixon JM, Revicki DA.

CNS Drugs. 2006;20(7):591-9. Review.

PMID:
16800717
17.

The expert consensus guideline series. Treatment of behavioral emergencies 2005.

Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP; Expert Consensus Panel for Behavioral Emergencies 2005.

J Psychiatr Pract. 2005 Nov;11 Suppl 1:5-108; quiz 110-2.

PMID:
16319571
18.

A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in taiwan.

Gau SS, Chung CH, Gau CS.

J Clin Psychopharmacol. 2008 Jun;28(3):271-8. doi: 10.1097/JCP.0b013e3181723713.

PMID:
18480683
19.

Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.

Edwards NC, Rupnow MF, Pashos CL, Botteman MF, Diamond RJ.

Pharmacoeconomics. 2005;23(3):299-314.

PMID:
15836010
20.

Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.

Kongsakon R, Leelahanaj T, Price N, Birinyi-Strachan L, Davey P.

J Med Assoc Thai. 2005 Sep;88(9):1267-77.

PMID:
16536115
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk